Loading
Reactions around the moment a drug is given: chills, fever or breathlessness from antibodies (infusion reactions), true allergy (hypersensitivity, rarely anaphylaxis), and leakage of a damaging drug into tissue around the vein (extravasation).
Infusion reactions are common with first doses of rituximab, cetuximab, daratumumab and other antibodies (cytokine release from target cells) and with taxanes and platinum (hypersensitivity, rising with cumulative carboplatin exposure); premedication with antihistamines, steroids and paracetamol, slow initial rates and subcutaneous formulations (rituximab, daratumumab, atezolizumab, pembrolizumab) reduce them. Anaphylaxis to asparaginase or platinum leads to switching agents or desensitisation. Extravasation of vesicants (anthracyclines, vinca alkaloids) causes tissue necrosis and is why central venous access is used; dexrazoxane treats anthracycline extravasation. These are distinct from cytokine release syndrome after T-cell engagers, though mechanistically related.
Backbone ribbon from PDB 6VJA. RCSB PDB 6VJA. The ribbon widens where the chain is folded into a regular pattern and narrows where it is a loose loop.
Showing the molecule this term concerns: Rituximab.
Shares Cetuximab, Carboplatin.
Shares Daratumumab, Rituximab.
Shares Cetuximab, Carboplatin.
Shares Cetuximab, Carboplatin.
Shares Anthracyclines (doxorubicin, epirubicin), Carboplatin.
Shares Cetuximab, Carboplatin.
Shares Cetuximab, Carboplatin.
Shares Daratumumab, Rituximab.